Skip to main
GH
GH logo

GH Stock Forecast & Price Target

GH Analyst Ratings

Based on 21 analyst ratings
Buy
Strong Buy 38%
Buy 62%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Guardant Health, Inc. has demonstrated a robust two-year revenue compound annual growth rate (CAGR) of 28% projected from 2023 to 2025, indicating strong financial momentum. The company's growth is supported by anticipated advancements in colorectal cancer, breast cancer, and other indications, as well as the development of new monitoring applications and products like Reveal Ultra. Additionally, the expansion of reimbursement coverage for molecular residual disease (MRD) tests is expected to further enhance the company's commercial performance, leading to revised long-term revenue growth and margin assumptions in their financial projections.

Bears say

Guardant Health's recent medium-term revenue guidance for its Shield product has been perceived as underwhelming, raising concerns about the company's growth potential. Additionally, the organization faces significant risks related to regulatory approvals, reimbursement processes, and potential delays in product launches, which may adversely affect its stock performance. Increased research and development expenses, necessary for leveraging its Smart Liquid Biopsy platform and advancing product innovation, are likely to further strain financial stability in the near term.

GH has been analyzed by 21 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 62% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Guardant Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Guardant Health Inc (GH) Forecast

Analysts have given GH a Buy based on their latest research and market trends.

According to 21 analysts, GH has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $65.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $65.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Guardant Health Inc (GH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.